Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.
Saved in:
| Title: | Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial. |
|---|---|
| Authors: | Trauner M; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: michael.trauner@meduniwien.ac.at., Levy C; Division of Digestive Health and Liver Diseases and Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA., Tanaka A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan., Goodman Z; Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA., Thorburn D; The Sheila Sherlock Liver Centre and UCL Institute of Liver and Digestive Health, Royal Free Hospital, London, UK., Joshi D; Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK., Salminen K; Division of Gastroenterology, Department of Medicine, Turku University Hospital, Turku, Finland., Yimam K; Department of Hepatology and Liver Transplantation, California Pacific Medical Center, San Francisco, CA, USA., Isayama H; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Montano-Loza AJ; Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, AB, Canada., Caldwell S; Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA, USA., Danta M; School of Clinical Medicine, Faculty of Medicine, UNSW, Sydney, Australia; Department of Gastroenterology and Hepatology, St Vincent's Hospital, Sydney, NSW, Australia., Farkkila M; Clinic of Gastroenterology, Helsinki University, Helsinki University Hospital, Helsinki, Finland., Gallegos-Orozco JF; Division of Gastroenterology and Hepatology, University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, UT, USA., Gordon SC; Department of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, USA; Wayne State University School of Medicine, Detroit, MI, USA., Hinrichsen H; Gastroenterologisch-Hepatologisches MVZ Kiel, Kiel, Germany., Invernizzi P; Division of Gastroenterology, Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy., Vuppalanchi R; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA., Zhu K; Gilead Sciences, Foster City, CA, USA., Xu J; Gilead Sciences, Foster City, CA, USA., Liu X; Gilead Sciences, Foster City, CA, USA., Lu X; Gilead Sciences, Foster City, CA, USA., Crans G; Gilead Sciences, Foster City, CA, USA., Bolbolan S; Gilead Sciences, Foster City, CA, USA., Boyette L; Gilead Sciences, Foster City, CA, USA., Alani M; Gilead Sciences, Foster City, CA, USA., Barchuk WT; Gilead Sciences, Foster City, CA, USA., Watkins TR; Gilead Sciences, Foster City, CA, USA., Genovese MC; Gilead Sciences, Foster City, CA, USA., Bowlus CL; Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, CA, USA. |
| Source: | The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2026 Jan; Vol. 11 (1), pp. 46-58. Date of Electronic Publication: 2025 Oct 28. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
